Search

Advances from genome sequencing are paving the way to personalized treatment for leukemia and pre-leukemia

In acute myeloid leukemia (AML) our understanding of how modifications to DNA molecules that do not result in sequence change (i. e.

Read more

EHA at ICH meeting: Excessive bureaucracy harms patient safety and innovation

To solicit input from a wide range of non-ICH members about the revision of ICH E8(R1), ICH held a Public Meeting on ICH E8(R1) “General Considerations for Clinical Studies” (Silver Spring, USA, October 31, 2019).

Read more

EHA leads Tutorial in Kazakhstan for better understanding of lymphomas

EHA, in collaboration with the Kazakhstan Cancer Society (KCS) and Kazakh Institute of Oncology and Radiology (KazIOR), organized its very first tutorial together on March 14-16 in Almaty, Kazakhstan.

Read more

HARMONY: Innovative Medicines Initiative approves € 40 million project for better care of patients with hematologic malignancies

HARMONY will capture, integrate, analyze and harmonize anonymous patient data from high-quality multidisciplinary sources to unlock valuable knowledge on multiple myeloma (MM), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma (NHL), myelodysplastic syndromes (MDS)…

Read more

Harnessing new developments in genomics to improve outcome for children with poor prognosis leukemia

At the 19th Congress of the European Hematology Association (EHA), we will learn about the state-of-the-art in management of childhood AML.

Read more

Helping to shape Europe’s clinical trials landscape: EHA selected for ACT EU advisory group

Improving the design, efficiency and effectiveness of clinical trials is the objective of the Accelerating Clinical Trials in the European Union (ACT EU) initiative.

Read more